Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate

Published:2018-04 Issue:4 Volume:77 Page:488-494
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Annals of the Rheumatic Diseases

Author:

Matsuno Hiroaki,Tomomitsu Masato,Hagino Atsushi,Shin Seonghye,Lee Jiyoon,Song Yeong Wook

Funder

Korea Health Industry Development Institute

LG Chem, Ltd.

Mochida Pharmaceutical Co., Ltd

Publisher

Elsevier BV

Reference21 articles.

1. Recombinant human tumor necrosis factor receptor (p75) fc fusion protein (tnfr:Fc) in rheumatoid arthritis;Murray;Ann Pharmacother,1997

2. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review;Tracey;Pharmacol Ther,2008

3. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera;Matsuno;Rheumatology,2002

4. Binding and functional comparisons of two types of tumor necrosis factor antagonists;Scallon;J Pharmacol Exp Ther,2002

5. Tumor necrosis factor inhibitors - state of knowledge;Lis;Arch Med Sci,2014

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Etanercept Biosimilar Initiating for Etanercept-Naive Patients, Using Ultrasound, Clinical, and Biomarker Assessments in Outcomes of Real-World Therapy (ENPORT-NGSK Study): An Interventional, Multicenter, Open-Label, Single-Arm Clinical Trial;Journal of Clinical Medicine;2025-03-06

2. Efficacy of etanercept biosimilar switching from etanercept reference product, using ultrasound and clinical data in outcomes of real world therapy (ESCORT-NGSK Study);Drug Discoveries & Therapeutics;2025-02-28

3. 2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication;Modern Rheumatology;2025-01-17

4. Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis;Seminars in Arthritis and Rheumatism;2024-12

5. Efficacy, safety, and immunogenicity of biosimilars compared with the biologic etanercept in patients with rheumatoid arthritis: a systematic review and meta-analysis;Systematic Reviews;2024-11-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.7亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3